UK Bioscience Forum: Incentivize investors to hold their investment for more than 10 years

8 October 2014

One of the main messages from the keynote speech at the UK Bioscience Forum by Paul Drayson, chief executive of Drayson Technologies and previous minister for science and innovation, was that the country needs to give incentives for investors to hold their investment for more than 10 years. The subject of funding and of making the UK a welcome and productive place for bioscience companies to do business was echoed, repeatedly, throughout the day.

The state of the bioindustry

The BioIndustry Association’s (BIA) report on the State of the Nation, presented at the conference, showed that the UK leads Europe in terms of capital raised and the pipeline of products. The UK has raised £734 million ($1.1 billion) in innovation capital in the first half of 2014, which is set to be a banner year since the first half has already surpassed the total of £483 million of innovation capital raised in 2013. The UK remains the largest bioscience cluster in Europe, developing over 450 product candidates in 2013.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK